Semax research includes different amounts, populations and routes. A quantity reported in a stroke-rehabilitation study is not a standard dose for concentration or everyday cognitive performance. The sources below also do not establish a subcutaneous regimen by converting an intranasal amount.
Semax quantities reported in the reviewed human studies
| Study | Population and reported preparation | What was measured |
|---|---|---|
| Kaplan and colleagues, 1996 | Human volunteers; the abstract describes 0.25-1.0 mg by the intranasal route. | EEG responses and operator work efficiency. This is not a modern dose-finding trial establishing a universal cognitive-enhancement regimen. |
| Gusev and colleagues, 2018 | 110 people after ischemic stroke, divided by rehabilitation timing and Semax exposure. The abstract describes 6,000 micrograms daily in two ten-day courses separated by twenty days. | Plasma BDNF, motor performance and the Barthel functional index. The abstract does not specify the administration route, so this page does not assign one. |
| Lebedeva and colleagues, 2018 | 24 healthy volunteers: fourteen received intranasal 1% Semax and ten received placebo. | Resting-state fMRI before administration and five and twenty minutes afterward. The abstract reports a brain-network finding, rather than a daily dose or a demonstrated improvement in everyday cognition. |
The study populations and outcomes differ. Combining their quantities into one “beginner,” “standard” and “advanced” chart would imply a clinical dose-response relationship that these studies do not establish.
Micrograms, milligrams and percentage concentrations
One milligram equals 1,000 micrograms. The stroke study's 6,000 micrograms per day therefore equals 6 mg per day. That is a unit conversion describing the study, not a recommendation to use that amount.
A percentage concentration is different from a delivered dose. Calculating the mass delivered from a solution requires its concentration basis and the actual administered volume. A drop count or pump count cannot be converted accurately without the product's measured delivery volume.
Similarly, a powder vial's total mass does not establish the amount per administration. Reconstitution changes concentration; it does not determine an effective regimen or show that a different route gives equivalent exposure.
What the BDNF finding can and cannot tell us
The 110-person stroke-rehabilitation study reported higher plasma BDNF and associations with functional recovery. BDNF is a biological measurement, while the Barthel index assesses daily functioning in a rehabilitation setting. Neither result can be assigned automatically to healthy adults seeking improved focus.
From the FormBlends catalog
Semax
Nootropic peptide for focus, memory, and neuroprotection · From $44/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
Learn about Semax →Animal research is another separate category. A 2021 rat ischemia-reperfusion study examined brain protein expression and protective effects in that model. Rat brain-expression findings do not establish a human injection dose or a percentage improvement in memory.
Why a brain scan is not a dosing guideline
The small fMRI study reported a difference in part of the resting-state default mode network after intranasal administration. A measured network change is not the same endpoint as better school performance, work productivity or treatment of a diagnosed cognitive disorder.
Its short observation period also cannot establish the effect of taking a product every day for months. An acute experiment, a rehabilitation course and a long-term regimen need separate evidence.
Does intranasal research establish a subcutaneous equivalent?
The reviewed sources do not provide a controlled human comparison establishing equivalent intranasal and subcutaneous amounts. A route-conversion ratio therefore cannot be derived from these findings.
The same restriction applies to modified compounds marketed under related names. A study identified as Semax should not be assigned automatically to an acetylated or amidated variant without evidence for that specific preparation.
Frequently asked questions
Was the stroke-study amount 600 micrograms?
The cited 2018 abstract reports 6,000 micrograms per day, equal to 6 mg, in its rehabilitation population. Dropping a zero changes the reported quantity tenfold.
Does the 1996 intranasal range define a universal daily dose?
No. It describes amounts in that research report. It does not establish a standard schedule for all people or purposes.
Does a 1% product label tell me how many micrograms are in a spray?
Not without the concentration basis and actual delivered volume. Percentage, solution volume and delivered mass are different measurements.
Is a dose-escalation or cycling schedule established by these studies?
The reviewed studies do not establish the common multi-tier home dosing charts or indefinite cycling schedules.
Sources
- Kaplan and colleagues, Synthetic ACTH analogue Semax displays nootropic-like activity in humans, 1996
- Semax in patients at different stages of ischemic stroke, 2018
- Effects of Semax on the Default Mode Network of the Brain, 2018
- Semax brain protein expression in a rat ischemia-reperfusion model, 2021
Ready when you are
Semax
Nootropic peptide for focus, memory, and neuroprotection · From $44/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
Learn about Semax →